Posts

Posted on

Jack Nathan Health Acquires Writi, a Leading Technology Start-Up for Long Term Care Homes

Jack Nathan Health Acquires Writi, a Leading Technology Start-Up for Long Term Care Homes

TORONTO–(BUSINESS WIRE)–Jack Nathan Medical Corp. (TSXV: JNH) (“Jack Nathan Health” “JNH” or the “Company”) announced today that:

  • JNH has closed an agreement (the “Acquisition”) to acquire Writi Inc. (“Writi”).
  • Writi is a cloud-based medication-management software platform, available on mobile devices and web platforms. The platforms support the secure digital communication, record maintenance and workflow of resident-related orders and documentation. Information flows seamlessly into the patient’s health record and is securely accessible by local and remote healthcare partners.
  • Writi’s Virtual Healthcare platform facilitates secure communication and documentation of resident care, supports billing/reporting associated with virtual healthcare and is integrated with PointClickCare, Telus Health (Kroll™ Pharmacy Management Solution) and MED e-care.
  • Writi is helping to contain the spread of COVID-19 with remote virtual check-ups from physicians and nurse practitioners, treating patients and prescribing using virtual billing, prescription fulfilment, and integration with various EMRs. In addition, prescribers and healthcare workers can check in on patients in isolation and assess and treat patients remotely.
  • Writi service platform, in its early stage, is scaling, and is used in long-term care (“LTC”) homes by over 800 frontline healthcare workers, serving 15 locations and 1598 resident beds.
  • Writi has a stable and growing recurring revenue base, receiving a monthly recurring SaaS fee per resident beds, in LTC homes.
  • Writi provides virtual visit care, remote prescribing, with notes and provincial billing reports capability.
  • Writi is compliant with the Personal Health Information Protection Act (“PHIPA”) and one of the few digital platforms that meet the strict security and regulatory requirements for use in LTC homes.
  • The Acquisition accelerates JNH’s technology roadmap including bringing hospital-quality care to the home and completing the Circle of Healthcare™.

“Writi has created a fast-growing virtual healthcare platform with potential for large scale success and adoption from the heavily regulated LTC industry. In a short time, they have seen impressive pickup with 15 LTC Homes and 1598 resident beds served on their platform,” said George Barakat, CEO of Jack Nathan Health. “With Writi and JNH in sync, we will be able to leverage our physician network and pharmacy partners to offer better care for seniors. In addition to helping Writi add more LTC homes we plan to integrate Writi across all Jack Nathan Health platforms, providing at home health care. This technology roadmap includes monitored home patient care, connected health care devices, delivery of RX prescriptions, physician scheduling in our clinics and via telemedicine, delivery and recommendations for our practitioners’ products and dietary needs including grocery. In addition, we intend to leverage the Writi platform to all Canadians through our large and growing national clinic footprint. We believe that all Canadians should have more options to ‘Live Their Best Lives’, take care of their loved ones and provide a better Circle of Healthcare™ for their families and communities.”

The LTC system is strained by overcrowding and limited resource. Today, people over 65, accounting for 17% of the Canadian population and 44% of healthcare costs. There are over 700 LTC homes and over 1,000 senior care homes in Ontario alone. By 2036 a quarter of Canadians will be over 65 putting additional pressure on the entire Canadian healthcare system.1 COVID-19 has only exacerbated these issues.

Roughly half of Canada’s COVID-19 deaths have occurred in long-term care homes — and the numbers are only increasing. Writi’s Virtual Healthcare platform fosters efficiency and communication, even in remote work, among healthcare professionals so that they may focus on what matters most – saving residents. The Writi platform, implemented at several LTC homes where COVID-19 has been severe, has garnered praise from the home’s senior leaders for their support in the fight.

The Writi Virtual Healthcare platform reduces prescribing time by 20% and nursing order-processing time by 43%, drastically reducing the administrative burden on practitioners and allowing more patient care time. The platform includes mobile access, telehealth, e-prescribe, electronic order-processing, patient charting and integrates with Electronic Medical Records (“EMRs”). To learn more about Writi, please visit writi.ca or watch a short video on the Writi Solution.

Parth Patel, Co-founder of Writi commented, “We are excited to be part of a global healthcare leader that shares our mission and values. We have a shared focus on leveraging technology to improve communication, healthcare access, and medication accuracy. Partnering with JNH will strengthen our ability to assist senior living and LTC providers, and their pharmacy partners, resulting in enhanced quality of care for seniors and their loved ones.”

Under the terms of the Acquisition, Jack Nathan Health has agreed to pay a purchase price of 1,000,000 Jack Nathan Common shares with certain escrow and claw back provisions.

About Jack Nathan Medical Corp.

Jack Nathan Medical Corp., operating as Jack Nathan Health®, is one of Canada’s largest healthcare networks. Jack Nathan Health® is an innovative healthcare company that is improving access for millions of patients by co-locating physician and ancillary medical services conveniently located inside Walmart® stores.

Jack Nathan Health® provides an exceptional level of patient care, made possible through patient-centric physicians, a variety of medical services, technology, and programs, designed to put patients first. Our mission is to provide everyone access to the finest quality retail medical centres, with both in-clinic physicians and digital telemedicine, so you and your loved ones can “Live Your Best Life”.

Jack Nathan Health® was established in 2006 and continues to expand its international footprint, delivering exceptional, state-of-the-art, turn-key medical centres in 76 Walmart locations across Canada including British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, and Quebec, as well as six locations operating in Mexico and 50 new locations opening in 2021.

For more information, visit www.jacknathanhealth.com or www.sedar.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to Jack Nathan are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to them, and are subject to certain risks, uncertainties, and assumptions Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include but are not limited to changes in economic conditions or financial markets; increases in costs; litigation; legislative and other judicial, regulatory, political, and competitive developments; the economic and business impact of Covid19 and operational difficulties. This list is not exhaustive of the factors that may affect forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

1https://www150.statcan.gc.ca/n1/pub/11-402-x/2012000/chap/seniors-aines/seniors-aines-eng.htm

IR contacts:

David Berman, CFO, [email protected]

or

Mark Kuindersma, LodeRock Advisors, [email protected]

PR & Marketing contact:

Jennifer Usher, Vice President Marketing & Communications, [email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Managed Care Software Other Health General Health Mobile/Wireless Internet Pharmaceutical Data Management Technology Hospitals Nursing Practice Management Health

MEDIA:

Logo
Logo
Posted on

Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology

Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology

Exclusive License Focused on China and Other Key Asia-Pacific Markets

CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–
Strand Therapeutics, a privately held developer of next-generation, programmable mRNA therapeutics for cancer and other diseases, and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that they have entered into an option and license agreement aimed at developing and commercializing Strand’s innovative, multi-functional mRNA treatments for solid tumors. BeiGene has secured an option to an exclusive license to develop and commercialize in Asia (excluding Japan), Australia, and New Zealand up to two immuno-oncology programs using Strand’s intratumoral or systemic delivery mechanism, which is designed to deliver a tumor microenvironment-modifying mRNA directly to the tumor site.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005317/en/

Strand has developed the first platform for the creation of programmable, long-acting mRNA therapeutics capable of delivering multi-functional treatments for deadly diseases, with an initial aim of developing potentially curative treatments for solid tumor cancers. The company’s self-replicating mRNAs are bioengineered to enable precise control of the location, timing, intensity, and duration of therapeutic protein expression for improved efficacy and lower toxicity.

“BeiGene is a recognized global leader in the development and commercialization of innovative, high-quality cancer therapeutics,” said Jacob Becraft, Ph.D., Co-founder and Chief Executive Officer of Strand. “This collaboration between our two companies provides strong validation of Strand’s next-generation mRNA platform and our work to advance mRNA-based medicines beyond vaccines into potentially curative therapies.”

“We look forward to working closely with BeiGene’s unsurpassed clinical team to accelerate the development of our solid tumor immuno-oncology therapies,” said Tasuku Kitada, Ph.D., Co-founder, President, and Head of R&D of Strand. “The aim of both our companies is to increase patient access to cutting-edge therapeutics by providing safe and effective treatments that are more easily administered, cost-effective, and scalable.”

“Strand’s programmable mRNA technology is incredibly exciting as a cutting-edge therapeutic platform and is expected to help us build novel mRNA-based immuno-oncology therapeutics for the treatment of cancer. We look forward to exploring this technology further and to collaborating with Strand as we advance up to two development programs with this new approach,” said Lusong Luo, Ph.D., Senior Vice President of External Innovation at BeiGene.

Under the terms of the agreement, Strand will receive an upfront cash payment of $5 million and will also be eligible to receive additional near-term payments totaling up to $28 million, inclusive of BeiGene’s exercise of its options to the two programs following initial proof-of-concept studies. Additionally, Strand is eligible to receive payments from BeiGene based upon the achievement of certain development, regulatory, and sales milestones for a total deal value of up to $277 million, together with tiered royalties on any product sales in the licensed territory. In connection with the agreement, Strand also received investments of $10 million, including $5 million from BeiGene.

About Strand Therapeutics

Strand Therapeutics is an emerging biopharmaceutical company poised at the forefront of mRNA therapeutics and synthetic biology. The company has created the first platform for programmable, long-acting mRNA therapeutics for cancer and other diseases that are poorly addressed by traditional approaches. Bioengineered for high efficacy and low toxicity, Strand’s next-generation mRNA therapies deliver multi-functional treatments for deadly diseases. The company’s initial focus is the development of mRNA therapies that act through multiple mechanisms to deliver potentially curative treatments for solid tumors. Strand is also developing programmable mRNA for the generation of cell therapies capable of greatly expanding patient access to the technology in a cost-effective, re-doseable, off-the-shelf form. Strand Therapeutics was founded in 2017 by world leading mRNA researchers from the MIT Synthetic Biology Center, creators of the field of mRNA-based synthetic biology. The company is based in Cambridge, MA. For more information, visit our website at www.strandtx.com.

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,000+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

BeiGene Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the further advancement of the mRNA technology and mRNA-based immuno-oncology programs under the agreement with Strand, BeiGene’s option to obtain an exclusive license and the condition that the programs demonstrate proof of concept, the parties’ commitments and the potential benefits of the collaboration, potential payments payable to Strand, and other information that is not historical information. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene’s reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on the Company’s clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

BeiGene Contacts:

Investor Contact

Craig West

+1 857-302-5189

[email protected]

Media Contact

Liza Heapes or Vivian Ni

+1 857-302-5663 or +1 857-302-7596

[email protected]

Strand Therapeutics Contact:

Michelle Linn

+1 774-696-3803

[email protected]

KEYWORDS: Massachusetts China United States North America Asia Pacific

INDUSTRY KEYWORDS: Oncology Health Genetics Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Logo
Logo
Posted on

Elanco Begins Next Phase of Integration Post-Bayer Animal Health Acquisition; Executive Committee Member Sarena Lin to Depart

Elanco Begins Next Phase of Integration Post-Bayer Animal Health Acquisition; Executive Committee Member Sarena Lin to Depart

Transformation efforts will streamline and localize as next phase of integration is realized

GREENFIELD, Ind.–(BUSINESS WIRE)–
Today Elanco Animal Health Incorporated (NYSE: ELAN) announced that executive vice president of Transformation and Technology, Sarena Lin, will take a role outside of the company at the end of January. Lin has led the company’s stand up and integration efforts over the last year, helping position Elanco for its final phases of integration and value capture.

Joining Elanco as head of North American operations in 2018, Lin most recently oversaw the creation of the company’s technology infrastructure post-separation from Eli Lilly and Company (“Lilly”), as well as the successful closure and first phases of integration of Bayer’s animal health business into Elanco. This included the completion of Elanco’s own IT operations and simultaneous build out of two Enterprise Resource Planning (ERP) systems to operate the standalone and newly acquired business.

“The work done by Sarena’s team to stand Elanco up as an independent company has helped us become a stronger, stable entity,” said Jeffrey N Simmons, Elanco president and chief executive officer. “I want to thank Sarena for her valuable contributions and wish her well. Because of the transformation work she led with her team, we are well positioned to begin the next phase of integration.”

As the integration enters its next phase, technology and transformation work will streamline, localizing ownership of the structure and technology to ensure affiliates are equipped to address the diverse needs of customers. Responsibility for finance and productivity initiatives related to the integration and the IT organization will shift to Todd Young, chief financial officer.

These changes are a key milestone in Elanco’s progression through the Innovation, Productivity and Portfolio (IPP) strategy. As the company outlined at its first Investor Day last month, the next phase of transformation will create shareholder value and increase productivity through:

  • Accelerated value capture opportunities through the Bayer Animal Health integration to deliver $300 million in synergies by 2023, two years faster and at the high end of the company’s earlier commitment.
  • Execution of the next phase of the multi-year productivity agenda across the manufacturing network to achieve an additional $100 million in cost savings/avoidance by 2023.
  • A strengthened synergy between business and board, including an enhanced scope of the Board’s Finance Committee to emphasize operational initiatives, merger and acquisition integration, financial matters and margin expansion and related areas of oversight. Additionally, the company created a board-level Innovation, Science and Technology Committee focused on advancing and augmenting the product pipeline.

Additionally, the company outlined near-term growth drivers including:

  • Eight expected product launches in 2021, one of which has blockbuster potential.
  • Portfolio balance across species and geography.
  • Key enablers including omnichannel leadership, pricing, and digital ecosystem.

“There has been a great deal of momentum created as we move into 2021,” Simmons continued. “We have been in a state of physical growth over the past few years, and now we are shifting to nurture that growth and its investment to return even greater value for shareholders and customers alike.”

ABOUT ELANCO

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability/ESG Pledges – all to advance the health of animals, people, and the planet. Learn more at www.elanco.com

Forward Looking Statement

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about development and reflects Elanco’s current belief. Forward-looking statements are based on our current expectations and assumptions regarding our business and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. For further discussion of these and other risks and uncertainties, see Elanco’s most recent filings with the United States Securities and Exchange Commission. Except as required by law, Elanco undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Elanco and the diagonal bar logo are trademarks of Elanco and its affiliates.

© 2021 Elanco or its affiliates.

Media Contact: Colleen Parr Dekker +1 (317) 989.7011 or [email protected]

Investor Contact: Tiffany Kanaga +1 (302) 897.0668 or [email protected]

KEYWORDS: Indiana United States North America

INDUSTRY KEYWORDS: Agriculture Health Natural Resources Veterinary

MEDIA:

Logo
Logo
Posted on

Mastercard Pioneers Cloud Tap on Phone, its First Pilot of Cloud Point of Sale (POS) Acceptance Technology

Mastercard Pioneers Cloud Tap on Phone, its First Pilot of Cloud Point of Sale (POS) Acceptance Technology

  • Mastercard and its partners move services to the cloud, democratizing access to payments technologies.
  • Move unlocks opportunities for partners worldwide to enable contactless payments acceptance via a mobile phone.

PURCHASE, N.Y.–(BUSINESS WIRE)–
Mastercard has partnered with NMI and Global Payments Inc. to launch its first live Cloud Tap on Phone pilot with Computer Engineering Group (CEG), a Napa, Calif.-based independent IT Services provider. Cloud Tap on Phone is one of Mastercard’s innovative next generation acceptance products, with the software hosted on Microsoft’s Azure cloud platform.

Mastercard has been spearheading the transition to contactless payments for years. The demand for faster, more convenient, safe, and now cleaner ways to pay has driven the transition to contactless, and it’s a one-way street with touch-free experiences expected to be permanent for consumers and businesses even after the pandemic ends. In fact, in the third quarter of 2020, contactless penetration represented 41% of in-person purchase transactions globally, up from 37% in the second quarter and 30% a year ago.

With Tap on Phone, any business – regardless of size – can deliver new and best-in-class contactless consumer experiences using a device they already own: a smartphone. Tap on Phone democratizes point-of-sale technology by turning an Android smartphone or tablet into an acceptance device, allowing businesses to accept contactless payments minimizing the need to invest in hardware terminals or extra features. Merchants can offer enhanced and accelerated curbside pick-up or payment on delivery, or provide faster line-skipping checkout in-store, options that are increasingly important as consumers look to touch-free cash alternatives.

With the introduction of Cloud Point of Sale (POS), Mastercard is enhancing its Tap on Phone product and empowering ecosystem partners to develop their own cloud-based products with new tools and capabilities. Cloud POS moves key parts of the acceptance software – the components1 which enable the processing of contactless transactions and certain security functions – from the individual smartphone to the cloud, offering robust security, reducing development and maintenance costs, and creating scalable distribution channels by allowing immediate connectivity to partners. Cloud POS also becomes a new channel for Mastercard and our partners to bring value added services to customers and businesses.

Mastercard will make its pre-certified Cloud POS software development kits (SDKs) openly available in multiple cloud environments, encouraging solution providers, fintechs, acquirers and processors to innovate and co-create new cloud-first products. Mastercard’s pilot with CEG represents the first live deployment of Mastercard Cloud Tap on Phone anywhere in the world.

“We continue to see an accelerating shift to digital payments, with businesses of all sizes wanting to provide swift, secure, compelling point-of-sale experiences. Cloud POS enables us to make these experiences available to our partners with greater speed and efficiency,” said Milan Gauder, Global Head of Mastercard’s Acceptance Solutions Group. “Our partners are the center of everything we do, and our trusted technology powers innovative experiences, choice, flexibility and certainty, creating the products they need. Mastercard’s Cloud Tap on Phone delivers on our promise of ground-breaking products and innovation.”

Mastercard has convened an ecosystem of partners to launch Cloud Tap on Phone.

  • Leading payments enablement technology company NMI operates as a key integration partner and distributor.
  • Global Payments, a leading worldwide provider of payment technology and software solutions, will provide point of sale acceptance technology.
  • Continuing the company’s commitment to empower small businesses, CEG, an independent IT services company from California, serviced by an ISO BNG Payments, becomes the first company to pilot Mastercard’s Cloud Tap on Phone.

Development of Cloud POS technology and the Cloud Tap on Phone product has been spearheaded by Mastercard Labs, the company’s new product development arm. The company’s pilot with CEG follows live product testing on Mastercard’s own Purchase, N.Y. campus. Cloud POS is a product of Mastercard’s multi-cloud strategy, meeting businesses, consumers, financial institutes and partners in the cloud with innovative applications and services.The company will conduct further Cloud Tap on Phone pilots and commercial deployments in other markets in 2021. Currently, Mastercard’s Tap on Phone solution is in 16 markets across Europe, Asia Pacific, Latin America, North America and Middle East & Africa. Pilots are taking place with partners in Costa Rica, Hong Kong, Poland, Kazakhstan, Romania, Canada, Belarus, Russia, Turkey, United Kingdom, among other countries.

Notes to Editors:

What Our Partners are Saying

“Tap on Phone technology perfectly complements the acceleration of contactless payments in the U.S. market. This is a ground-breaking step in creating a world that enables merchants to turn their smartphones into a payment acceptance device without the need of an externally paired physical card reader.” – Nick Starai, Chief Strategy Officer, NMI

“The pandemic has permanently shifted the way global commerce operates, forcing companies to respond to increased demands for safe commerce solutions, such as mobile ordering and contactless payments. These waves of innovation will continue to accelerate, driving more and more technological advances across the payments industry. As an innovation leader in the payments industry, we are proud to partner with Mastercard on the new Cloud POS acceptance technology solution that will better equip merchants of all sizes to provide a faster, safer and more secure experience to help better serve consumers and their preferences for more advanced digital commerce solutions.” – Jim Egbert, Senior Vice President,Business Development & Strategic Partnerships, Global Payments

“CEG is very excited with the opportunity to work on the Mastercard pilot program. We are looking forward to using the contactless tap on phone technology to enhance our service experience with our retail customers. As a technology company we are always interested in exploring ways to stay at the cutting edge of technology development for our business and our IT customers. The Mastercard Tap on Phone program fits the bill!” – Eric Ross, General Manager, Computer Engineering Group (CEG)

“We have been selling and supporting a wide range of mobile POS software and hardware solutions since the inception of mPOS. BNG Payments is constantly striving to increase our support excellence, and one way to do this is to find new and innovative ways to minimize hardware and software issues. With traditional solutions, we are relying on Bluetooth or audio jack connected credit card acceptance devices that are all prone to connectivity issues between the device and smartphone, causing merchants to have transaction issues and down time. With Cloud Tap on Phone, we are reducing potential failure points to just a smartphone and data connection as well as reducing upfront cost by eliminating the need for additional hardware. This will be the future of mobile card-present transactions, and I am happy to see that merchants and cardholders stand to gain the most from this innovation.” – Ryan Theis, Chief Strategy Officer, BNG Payments

[1] An EMV Kernel is a set of interface routines, security and control functions, and logic defined in EMVCo Standard (www.emvco.com), to interact with a contact or contactless payment device, for instance a card or mobile, and retrieve the necessary data for the transaction authorization.

About Mastercard (NYSE:MA):

Mastercard is a global technology company in the payments industry. Our mission is to connect and power an inclusive, digital economy that benefits everyone, everywhere by making transactions safe, simple, smart and accessible. Using secure data and networks, partnerships and passion, our innovations and solutions help individuals, financial institutions, governments and businesses realize their greatest potential. Our decency quotient, or DQ, drives our culture and everything we do inside and outside of our company. With connections across more than 210 countries and territories, we are building a sustainable world that unlocks priceless possibilities for all.

About NMI:

NMI is one of the world’s leading card payment gateways, processing over 1.2 billion transactions a year from retail POS, e-commerce and self-service terminals. Our mission is to use our expertise to enable more payments, in more ways, and in more places, all with the utmost security and reliability. To do this, we provide ISOs, fintech innovators, and technologists with the software tools to easily work with us. It gives them the freedom to focus on what they do best, liberates them from restricted payment methods, and gives them access to the latest payment technology now and in the future. Our team spans the globe and has a twenty-year track record of delivering innovative payment solutions across specific retail sectors and has unparalleled experience in EMV technology.

About Global Payments:

Global Payments Inc. (NYSE: GPN) is a leading pure play payments technology company delivering innovative software and services to our customers globally. Our technologies, services and employee expertise enable us to provide a broad range of solutions that allow our customers to operate their businesses more efficiently across a variety of channels around the world.

Headquartered in Georgia with nearly 24,000 employees worldwide, Global Payments is a member of the S&P 500 with worldwide reach spanning over 100 countries throughout North America, Europe, Asia Pacific and Latin America. For more information, visit www.globalpaymentsinc.com and follow Global Payments on Twitter (@globalpayinc), LinkedIn and Facebook.

Katie Priebe, Global Communications, Mastercard

+1 (914) 707-9822 | [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Software Networks Finance Banking Data Management Professional Services Technology Security

MEDIA:

Logo
Logo
Posted on

Plymouth Industrial REIT Adds REIT Veteran John Guinee to Board of Directors

Plymouth Industrial REIT Adds REIT Veteran John Guinee to Board of Directors

BOSTON–(BUSINESS WIRE)–
Plymouth Industrial REIT, Inc. (NYSE: PLYM) announced it has appointed John W. Guinee III to the Board of Directors. Mr. Guinee will serve as an independent director and will be a member of the Company’s Audit Committee.

Mr. Guinee was most recently Managing Director at Stifel, where he covered over 40 REITs in the office, industrial, multifamily and diversified property sectors. During his 15-year career as a sell-side analyst, he led the creation of new valuation methods for REITs, including estimating premiums and discounts to replacement cost and estimating the value creation of REITs over time. Prior to that time, he was Executive Vice President and Chief Investment Officer at Duke Realty, and Executive Vice President and Chief Investment Officer at Charles E. Smith Residential Realty during periods of significant growth and transformation for both companies. He also served for eleven years as Managing Director at LaSalle Investment Management and LaSalle Partners. He began his real estate career as a development officer at Hines in San Francisco. Mr. Guinee currently serves on the Artemis Real Estate Partners Advisory Board, as well as the board of Irvine Nature Center.

Jeff Witherell, Chairman and Chief Executive Officer of Plymouth, noted, “As we conducted our search for potential additions to the board, we recognized that John’s unique perspective as a REIT research analyst on the sell-side and buyside and as a chief investment officer for two REITs, made him a very compelling candidate. John has extensive experience in the REIT industry and is passionate about the industrial sector and the opportunities we have ahead of us. We look forward to his counsel and contributions to our continued growth.”

John Guinee added, “I could not be more excited to help Jeff and a very high-quality team at Plymouth Industrial REIT create more shareholder value. The low basis, value-add investment strategy is unique, and perhaps underappreciated, in the industrial REIT space. Plymouth offers an excellent entry point for investors relative to the larger industrial REITs.”

About Plymouth

Plymouth Industrial REIT, Inc. is a vertically integrated and self-managed real estate investment trust focused on the acquisition and operation of single and multi-tenant industrial properties located in secondary and select primary markets across the United States. The Company seeks to acquire properties that provide income and growth that enable the Company to leverage its real estate operating expertise to enhance shareholder value through active asset management, prudent property re-positioning and disciplined capital deployment.

Forward-Looking Statements

This press release includes “forward-looking statements” that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and of Section 21E of the Securities Exchange Act of 1934. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release, which are not strictly historical statements, including, without limitation, statements regarding management’s plans, objectives and strategies, constitute forward-looking statements. Such forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statement, many of which may be beyond our control. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “plan,” “seek,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe” or “continue” or the negative thereof or variations thereon or similar terminology. Any forward-looking information presented herein is made only as of the date of this press release, and we do not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.

Tripp Sullivan

SCR Partners

(615) 942-7077

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Logo
Logo
Posted on

J2 Global to Announce Fourth Quarter and Year-End 2020 Earnings

J2 Global to Announce Fourth Quarter and Year-End 2020 Earnings

LOS ANGELES–(BUSINESS WIRE)–
J2 Global, Inc. (NASDAQ: JCOM), a leading Internet information and services company, will release its Fourth Quarter and Year-End 2020 Earnings at 6:00PM ET on Thursday, February 11, 2021. Additionally, J2 Global invites the public, members of the press, the financial community, stockholders and other interested parties to listen to a live audio Webcast of its Fourth Quarter and Year-End 2020 Earnings Call at 8:30AM ET on Friday, February 12, 2021.

Vivek Shah, chief executive officer, and Scott Turicchi, president and chief financial officer, will host the call. Materials presented during the call will be posted on the Company’s web site at j2global.com and furnished as an exhibit to the Company’s 8-K filed with the Securities and Exchange Commission pursuant to Regulation FD in connection with the Company’s earnings announcement.

What:

 

J2 Global, Inc. Fourth Quarter and Year-End 2020 Earnings Release and Call

 

 

 

When:

 

Earnings Release on February 11, 2021, at 6:00PM (ET)

 

 

Earnings Call on February 12, 2021, at 8:30AM (ET)

 

 

 

Where:

 

www.j2global.com or dial in at (844) 985-2014

Questions for the conference call will be taken via email at [email protected] and can be sent anytime prior to or during the Webcast. If you are unable to attend the live Webcast, the conference call and presentation materials will be archived at www.j2global.com.

About J2 Global®

J2 Global, Inc. (NASDAQ: JCOM) is a leading internet information and services company consisting of a portfolio of brands including IGN, Mashable, Humble Bundle, Speedtest, PCMag, RetailMeNot, Offers.com, Spiceworks, Everyday Health, BabyCenter and What To Expect in its Digital Media business and eFax, eVoice, iContact, Campaigner, Vipre, IPVanish and KeepItSafe in its Cloud Services business. J2 reaches more than 230 million people per month across its brands. As of December 31, 2019, J2 had achieved 24 consecutive fiscal years of revenue growth. For more information about J2, please visit www.j2global.com.

Scott Turicchi

(800) 577-1790

J2 Global, Inc.

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Communications Technology Other Communications Internet Publishing

MEDIA:

Logo
Logo
Posted on

Red Robin Gourmet Burgers, Inc. Provides Business Update

Red Robin Gourmet Burgers, Inc. Provides Business Update

Reiterates Progress Made Towards Strategic Objectives

Company to Present at the 23rd Annual ICR Conference Today

GREENWOOD VILLAGE, Colo.–(BUSINESS WIRE)–
Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) (“Red Robin” or the “Company”), a full-service restaurant chain serving an innovative selection of high-quality gourmet burgers in a family-friendly atmosphere, today provided a business update, including preliminary, unaudited comparable restaurant revenue results for the fourth quarter ended December 27, 2020.

Paul J.B. Murphy III, Red Robin’s President and Chief Executive Officer, said, “During an unprecedented year due to the pandemic, we achieved a great deal, strengthening Red Robin’s operational execution, business model and liquidity. Our accomplishments are now enabling us to focus on creating long-term value for all shareholders as we enter 2021.”

Murphy concluded, “We began the fourth quarter with sequential improvement in comparable restaurant revenue compared to the third quarter, however, momentum stalled due to heightened dine-in and other restrictions in 43% of Company-owned restaurants including restaurants in our key states of California, Colorado, Oregon, and Washington. While the near-term is likely to remain volatile because of COVID-19, we are encouraged by recent state re-openings, and we expect indoor dining to be re-opened at 39 restaurants as of January 11th. We firmly believe Red Robin is well-positioned from both a sales and profitability standpoint when conditions normalize.”

Fiscal Year 2020 Accomplishments

Despite the COVID-19 pandemic, we made significant progress on our strategic plan during fiscal year 2020 to solidify our financial longevity and develop a more robust business model. Our accomplishments this past year include the following:

  • Significantly grew off-premise sales, which more than doubled over the prior year;
  • Continued Donatos® roll-out, now in 79 restaurants, a proven growth catalyst driving approximately $45 thousand per restaurant in incremental gross margin by the second year;
  • Structurally improved restaurant and enterprise level margin for the long-term compared to 2019;

    • Reduced our menu by over 1/3, improving operational execution and resulting in over $2 million in annual savings;
    • Implementing new management labor structure, including approximately $14 million in annual savings(1);
    • Optimizing our portfolio by completing lease negotiations for more than 75% of Company-owned restaurants resulting in 3% to 4% in occupancy expense savings over remaining lease terms, as well as permanently closing select restaurants; and
    • Reduced general and administrative expenses by more than 10%, or approximately $10 million.
  • Reduced costs are expected to result in enterprise margin improvement of over 100 basis points during 2022, as revenues approach pre-pandemic levels, while 2021 is expected to be lower primarily due to sales deleverage related to the pandemic and other inflationary costs;
  • Implemented our Total Guest Experience (“TGX”) hospitality model, resulting in highest ever Guest Satisfaction Scores; and
  • Increased website traffic by approximately 20%, and achieved best ever loyalty email engagement through enhanced segmentation and targeting.

Preliminary Fourth Quarter 2020 Net Comparable Restaurant Revenue Summary Compared to Fourth Quarter 2019

  • Net comparable restaurant revenue decreased 28.9%, primarily resulting from our operational shift in response to COVID-19, including limited occupant capacity, operating an off-premise only model at restaurants with closed dining rooms, and closed restaurants;
  • Off-premise sales increased 132% and comprised 43.9% of total food and beverage sales; and
  • Restaurants with Donatos® outperformed restaurants that do not currently offer Donatos® by over 500 basis points in net comparable restaurant revenue.

(1) Excludes labor savings associated with restaurants closed in 2019 and 2020.

Preliminary net comparable restaurant revenue and average net sales per restaurant for the Company’s 28-day accounting periods through our fourth fiscal quarter ended December 27, 2020 are as follows:

 

 

Period ended

Company-owned Restaurants(1)

1-Nov

29-Nov

27-Dec

Net Comparable Restaurant Revenues

 

(15.4)%

 

(28.8)%

 

(39.5)%

Average Net Sales per Restaurant

 

$42,509

 

$38,941

 

$35,716

# of Comparable Company-owned Restaurants

 

412

 

412

 

412

(1)Net sales performance for restaurants re-opened for full fiscal period presented. Restaurant count shown is as of the end of fiscal period presented. Sales performance at restaurants with reopened dining rooms was negatively impacted by rising COVID-19 cases resulting in new restrictions lowering or restricting dining room capacity in our key states of California, Colorado, Oregon, and Washington.

Company-owned Restaurants with Open Indoor Dining Rooms

As of December 27, 2020, the Company operated 246 indoor dining rooms with limited capacity, representing 57% of 431 currently open Company-owned restaurants.

Preliminary net comparable restaurant revenue and average net sales per restaurant for the Company’s 28-day accounting periods through our fourth fiscal quarter ended December 27, 2020 are as follows:

 

 

Period ended

Company-owned Restaurants with Open Indoor Dining Rooms(2)

1-Nov

29-Nov

27-Dec

Net Comparable Restaurant Revenues

 

(13.7)%

 

(20.7)%

 

(23.3)%

Average Net Sales per Restaurant

 

$42,778

 

$39,041

 

$40,578

# of Comparable Company-owned Restaurants

 

362

 

245

 

236

(2) Net sales performance for restaurants with open indoor dining rooms for the full fiscal period presented. Restaurant count shown is as of the end of the fiscal period presented.

Since the beginning of 2021, indoor dining rooms have been re-opened at 35 restaurants. We expect indoor dining to be re-opened at 4 additional restaurants as of January 11th.

Balance Sheet and Liquidity

As of December 27, 2020, the Company had total debt of $170.6 million, of which $9.7 million was classified as current. Outstanding borrowings under its credit facility were $169.8 million, in addition to amounts issued under letters of credit of $8.7 million. Amounts issued under letters of credit reduce the amount available under the credit facility but are not recorded as debt.

As of December 27, 2020, the Company had approximately $128 million in liquidity, including cash on hand and available borrowing capacity under its credit facility. Due to heightened restrictions and the increase in indoor dining room closures associated with the resurgence of COVID-19, the average cash burn rate for the fourth quarter of 2020 was approximately $1.5 million per week.

Virtual Conference Participation

The Company will participate in a virtual fireside chat discussion and hold investor meetings at the 2021 ICR Conference. Red Robin’s fireside chat discussion will be held on Monday, January 11, 2021, at 10:30 AM Eastern Time.

In conjunction with this press release, the Company has posted an investor presentation to its website. To access the presentation materials, please visit www.redrobin.com, select the “Company” section, then the “Investor Relations” link, then “News & Events” link, then the “Calendar of Events” link.

About Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB)

Red Robin Gourmet Burgers, Inc. (www.redrobin.com), is a casual dining restaurant chain founded in 1969 that operates through its wholly-owned subsidiary, Red Robin International, Inc., and under the trade name, Red Robin Gourmet Burgers and Brews. We believe nothing brings people together like burgers and fun around our table, and no one makes moments of connection over craveable food more memorable than Red Robin. We serve a variety of burgers and mainstream favorites to Guests of all ages in a casual, playful atmosphere. In addition to our many burger offerings, Red Robin serves a wide array of salads, appetizers, entrees, desserts, signature beverages and Donatos® pizza at select locations. It’s now easy to enjoy Red Robin anywhere with online ordering available for to-go, delivery and catering. There are more than 540 Red Robin restaurants across the United States and Canada, including those operating under franchise agreements. Red Robin… YUMMM®

Forward-Looking Statements

Forward-looking statements in this press release regarding the Company’s long-term value creation, indoor dining restrictions, capacity and timing, sales and profitability, Donatos® rollout and incremental margin growth, ability to annualize savings from menu, operational, and labor improvements, enterprise margin improvement and timing, guest satisfaction scores, preliminary results including net comparable restaurant revenue and average net sales per restaurant, and all other statements that are not historical facts, are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on assumptions believed by the Company to be reasonable and speak only as of the date on which such statements are made. Without limiting the generality of the foregoing, words such as “expect,” “believe,” “anticipate,” “intend,” “plan,” “project,” “could,” “will,” “estimate,” or “preliminary,” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Except as required by law, the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date and cautions investors not to place undue reliance on any such forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those described in the statements based on a number of factors, including but not limited to the following: the rapidly evolving nature of the COVID-19 pandemic and related containment measures, including the potential for a complete shutdown of Company restaurants; the extent of the impact of the COVID-19 pandemic or any other epidemic, disease outbreak, or public health emergency, including the duration, spread, severity, and recurrence of the COVID-19 pandemic; the duration and scope of COVID-19 related government orders and restrictions including in California where a substantial number of our restaurants are located; economic, public health, and political conditions that impact consumer confidence and spending, including the impact of COVID-19; the effect of the COVID-19 pandemic on labor, staffing, and changes in unemployment rate; the ability to achieve significant cost savings; the Company’s ability to defer lease or contract payments or otherwise obtain concessions from landlords, vendors, and other parties in light of the impact of the COVID-19 pandemic; the economic health of the Company’s landlords and other tenants in retail centers in which restaurants are located, suppliers, licensees, vendors, and other third parties providing goods or services to the Company; our ability to implement our seating expansion plans and the timing thereof, including factors that are under the control of government agencies, landlords and other third parties; adverse weather conditions in regions in which the Company’s restaurants are located and the timing thereof; the impact of political protests and curfews imposed by state and local governments; the effect of the COVID-19 pandemic on our supply chain and the cost, availability, and timing of obtaining key products, distribution, labor, and energy; the effectiveness of the Company’s marketing and menu strategies and promotions; the effectiveness of the Company’s strategic initiatives including service model, technology solutions, and sales building initiatives; the cost and availability of capital or credit facility borrowings; the adequacy of cash flows or available debt resources to fund operations; and other risk factors described from time to time in the Company’s Form 10-K, Form 10-Q, and Form 8-K reports (including all amendments to those reports) filed with the U.S. Securities and Exchange Commission.

For media relations questions:

Danielle Paleafico, Coyne PR

(973) 588-2000

For investor relations questions:

Raphael Gross, ICR

(203) 682-8253

KEYWORDS: United States North America Colorado

INDUSTRY KEYWORDS: Retail Restaurant/Bar Food/Beverage

MEDIA:

Posted on

Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw)Supply and New KRYSTEXXA® (pegloticase injection)Trials

Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw)Supply and New KRYSTEXXA® (pegloticase injection)Trials

– Company to present at 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 at 11:40 a.m. ET –

DUBLIN–(BUSINESS WIRE)–
Horizon Therapeutics plc (Nasdaq: HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and new KRYSTEXXA trials.

“Amid the most challenging environment we have ever faced, we had a record year of performance, exceeding our full-year 2020 net sales and adjusted EBITDA guidance, driven by the significant outperformance of TEPEZZA and the strong second-half performance of KRYSTEXXA,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “We delivered exceptional shareholder value while expanding our pipeline, with six programs expected to begin this year, including two new KRYSTEXXA programs. Additionally, we successfully completed the first increased scale TEPEZZA lot and we are on track to submit the resultant data to the FDA by the end of this month.”

Full-Year 2020 Preliminary Financial Results (unaudited)

  • Full-year 2020 net sales exceeded the high end of the Company’s guidance range of $2.12 billion to $2.14 billion; exceeding the high end of this guidance range represents year-over-year growth of more than 65 percent.
  • Full-year 2020 adjusted EBITDA exceeded the high end of the Company’s guidance range of $920 million to $940 million; exceeding the high end of this guidance range represents year-over-year growth of more than 95 percent and an adjusted EBITDA margin expansion of more than 700 basis points compared to 2019.
  • The outperformance was driven by strong net sales from its two key growth drivers, TEPEZZA, its biologic for the treatment of Thyroid Eye Disease (TED), and KRYSTEXXA, its biologic for the treatment of uncontrolled gout (chronic gout refractory to conventional therapy), as well as continued growth of its Rare Disease Business Unit.
  • TEPEZZA full-year 2020 net sales exceeded $800 million, with double-digit sequential growth in the fourth quarter of 2020.
  • KRYSTEXXA full-year 2020 net sales exceeded $400 million, with double-digit sequential growth in the fourth quarter of 2020.
  • Cash and cash equivalents at Dec. 31, 2020 were $2.08 billion and gross leverage was less than 1.1 times.

These preliminary financial results are unaudited and subject to adjustment. Horizon will report its final fourth quarter and full-year 2020 financial results in February.

TEPEZZA Supply Update

As previously announced on Dec. 17, 2020 the Company expects a short-term disruption in TEPEZZA supply as a result of government-mandated COVID-19 vaccine production orders related to Operation Warp Speed that dramatically restricted capacity available for TEPEZZA at its drug product contract manufacturer, Catalent. The Company anticipates that this drug supply shortage could last through the first quarter. The length of the TEPEZZA supply disruption will depend on whether future manufacturing slots are successfully completed as well as decisions by the U.S. Food and Drug Administration (FDA) regarding the increased scale manufacturing process of TEPEZZA.

The Company has made significant progress with TEPEZZA drug product supply over the last several weeks, successfully completing its first manufacturing lot at increased scale and beginning its second manufacturing lot at increased scale. The Company continues to expect to submit data this month from the first increased scale drug product manufacturing lot to the FDA for its review and approval.

Pipeline Update

The Company also announced two new KRYSTEXXA development programs it expects to begin in 2021, bringing the total number of programs in its pipeline to 14.

  • KRYSTEXXA monthly dosing trial: This open-label trial will evaluate a monthly dosing regimen of KRYSTEXXA, with methotrexate, to treat people with uncontrolled gout. The current dosing schedule for KRYSTEXXA is every other week. The goal of the trial is to explore whether a monthly dosing regimen can provide similar outcomes as the current dosing schedule.
  • KRYSTEXXA retreatment trial: This open-label trial will evaluate KRYSTEXXA, with methotrexate, in patients who have previously failed KRYSTEXXA. The goal of the trial is to evaluate whether patients can benefit from KRYSTEXXA, with methotrexate, after developing an immune response to KRYSTEXXA when taken alone. Patients who have previously failed KRYSTEXXA have limited options available to address their uncontrolled gout.

Presentation Information

Mr. Walbert will present at the J.P. Morgan Healthcare Conference at 11:40 a.m. ET on Jan. 12, 2021. The conference presentation will be webcast live and may be accessed by visiting Horizon’s website at http://ir.horizontherapeutics.com. A replay of the webcast will be available following the event.

About KRYSTEXXA

INDICATIONS AND USAGE

KRYSTEXXA (pegloticase injection) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.

Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

IMPORTANT SAFETY INFORMATION

WARNING: ANAPHYLAXIS AND INFUSION REACTIONS

Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA. Anaphylaxis may occur with any infusion, including a first infusion and generally manifests within 2 hours of the infusion. However, delayed-type hypersensitivity reactions have also been reported. KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions. Patients should be premedicated with antihistamines and corticosteroids. Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration of KRYSTEXXA. Serum uric acid levels should be monitored prior to infusions, and healthcare providers should consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.

The risk of anaphylaxis and infusion reactions is higher in patients who have lost therapeutic response.

Concomitant use of KRYSTEXXA and oral urate-lowering agents may blunt the rise of sUA levels. Patients should discontinue oral urate-lowering agents and not institute therapy with oral urate-lowering agents while taking KRYSTEXXA.

In the event of anaphylaxis or infusion reaction, the infusion should be slowed, or stopped and restarted at a slower rate.

Patients should be informed of the symptoms and signs of anaphylaxis and instructed to seek immediate medical care should anaphylaxis occur after discharge from the healthcare setting.

CONTRAINDICATIONS: G6PD DEFICIENCY ASSOCIATED HEMOLYSIS AND METHEMOGLOBINEMIA

Patients should be screened for G6PD deficiency prior to starting KRYSTEXXA. Hemolysis and methemoglobinemia have been reported with KRYSTEXXA in patients with G6PD deficiency. KRYSTEXXA should not be administered to these patients.

GOUT FLARES

An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy, including treatment with KRYSTEXXA. If a gout flare occurs during treatment, KRYSTEXXA need not be discontinued. Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.

CONGESTIVE HEART FAILURE

KRYSTEXXA has not been studied in patients with congestive heart failure, but some patients in the clinical trials experienced exacerbation. Caution should be exercised when using KRYSTEXXA in patients who have congestive heart failure, and patients should be monitored closely following infusion.

ADVERSE REACTIONS

The most commonly reported adverse reactions in clinical trials with KRYSTEXXA were gout flares, infusion reactions, nausea, contusion or ecchymosis, nasopharyngitis, constipation, chest pain, anaphylaxis and vomiting.

Please see Full Prescribing Information and Medication Guide for more information.

About TEPEZZA

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

Adverse Reactions

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache and dry skin.

For additional information on TEPEZZA, please see Full Prescribing Information at TEPEZZAhcp.com.

About Horizon

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

Note Regarding Use of Non-GAAP Financial Measures

EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are used and provided by Horizon as non-GAAP financial measures and include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on Horizon’s performance, operations, expenses, profitability and cash flows. Adjustments to Horizon’s GAAP figures as well as EBITDA exclude acquisition and/or divestiture-related expenses, charges related to the discontinuation of ACTIMMUNE development for Friedreich’s ataxia, gain or loss from divestiture, gain or loss from sale of assets, upfront, progress and milestone payments related to license and collaboration agreements, litigation settlements, loss on debt extinguishment, costs of debt refinancing, drug manufacturing harmonization costs, restructuring and realignment costs, the income tax effect on pre-tax non-GAAP adjustments and other non-GAAP income tax adjustments, as well as non-cash items such as share-based compensation, depreciation and amortization, non-cash interest expense, long-lived asset impairment charges and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon’s financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s estimated 2020 financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators Horizon’s management uses for planning and forecasting purposes and measuring the Company’s performance. For example, adjusted EBITDA is used by Horizon as one measure of management performance under certain incentive compensation arrangements. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Horizon has not provided a reconciliation of its full-year 2020 adjusted EBITDA estimates to an estimated net income (loss) outlook because certain items such as acquisition/divestiture-related expenses and share-based compensation that are a component of net income (loss) cannot be reasonably estimated due to the significant impact of the variability associated with the size or timing of acquisitions/divestitures and other factors related to Horizon’s year-end financial closing process. These components of net income (loss) could significantly impact Horizon’s actual net income (loss).

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to expected financial performance and operating results, including potential growth in net sales of certain of Horizon’s medicines; plans with respect to product development efforts, including planned clinical trials; potential market opportunity for, regulatory approval of and benefits of Horizon’s medicines and medicine candidates; and business and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon’s actual future financial and operating results may differ from its expectations or goals; the impacts of the COVID-19 pandemic and actions taken to slow its spread, including impacts on the supply and net sales of Horizon’s medicines and potential delays in clinical trials; Horizon’s ability to grow net sales from existing medicines and successfully launch new medicines; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; risks relating to Horizon’s ability to successfully implement its business strategies; risks inherent in developing novel medicine candidates and existing medicines for new indications; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Horizon’s filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

Tina Ventura

Senior Vice President, Investor Relations

[email protected]

Ruth Venning

Executive Director, Investor Relations

[email protected]

U.S. Media Contacts:

Geoff Curtis

Executive Vice President, Corporate Affairs & Chief Communications Officer

[email protected]

Ireland Media Contact:

Gordon MRM

Ray Gordon

[email protected]

KEYWORDS: New York Europe Ireland United States North America

INDUSTRY KEYWORDS: Health General Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference

Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference

OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:20 p.m. ET on Monday, January 11, 2021 / 7:20 a.m. JT on Tuesday, January 12, 2021. Investors and the general public are invited to listen to the live webcast with Christophe Weber, president and chief executive officer, here. A replay of the webcast will also be archived at the same location. A link to the webcast and slides for download will also be available on Takeda’s website at https://www.takeda.com/investors/ir-events/.

ABOUT TAKEDA PHARMACEUTICAL COMPANY LIMITED

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

Media Contacts:

Japanese Media

Kazumi Kobayashi

[email protected]

+81 (0) 3-3278-2095

Media Outside Japan

Holly Campbell

[email protected]

+1 617-588-9013

Investor Relations:

Christopher O’Reilly

[email protected]

+81 (0) 3-3278-2543

KEYWORDS: United States Japan North America Asia Pacific Massachusetts

INDUSTRY KEYWORDS: Oncology Health Genetics General Health Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020

Fourth quarter 2020 worldwide revenue of $57.7 million

(U.S. $47.4 million, International $10.3 million)

MASON, Ohio–(BUSINESS WIRE)–
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2020.

“We are pleased with our fourth quarter and full-year results which reflect the resiliency and strength of our team, as well as the overarching unmet need in our core markets. COVID-19 continues to impact our revenue as procedure volumes remain below pre-pandemic levels globally, and each resurgence of the virus is a reminder of the strain on healthcare resources,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “That said, the unwavering commitment of our people in support of our patient-first mission has been inspiring throughout the year.”

Mr. Carrel continued, “We ended 2020 in a very strong position financially and strategically, having made remarkable progress on many key initiatives across our business. Additionally, we are in a unique position of igniting multiple catalysts in 2021, including the hybrid Convergent procedure, EnCompass® Clamp, Cryo Nerve Block therapy expansion, and aMAZE™ clinical trial data, leading to significant market expansion and accelerated and durable growth rates over the long-term.”

Preliminary and Unaudited 2020 Financial Results

Preliminary, unaudited revenue for fourth quarter 2020 is expected to be approximately $57.7 million, reflecting a decrease of approximately 6% over the fourth quarter of 2019 (-7% on a constant currency basis). Preliminary revenue for full year 2020 is expected to be $206.5 million, reflecting a decline of approximately 11% over full year 2019 (-11% on a constant currency basis). Fourth quarter and full year 2020 revenue was impacted by the global decline in surgical procedures as a result of the COVID-19 pandemic.

On a sequential quarter basis, worldwide revenue for fourth quarter 2020 increased approximately 5% over third quarter 2020. The increase in revenue from third quarter 2020 reflects stabilizing procedure volumes for the majority of the fourth quarter.

Constant currency revenue is a non-GAAP measure. AtriCure will provide a reconciliation of non-GAAP measures to the related GAAP measure in the release of final 2020 results.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold left atrial appendage management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

Forward-Looking Statements

This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit http://www.atricure.com/fls as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. We do not undertake to update our forward-looking statements. Actual results could differ materially.

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

[email protected]

Lynn Pieper Lewis

Gilmartin Group

Investor Relations

(415) 937-5402

[email protected]

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Health Medical Devices Hospitals Surgery Other Health Clinical Trials Cardiology

MEDIA:

Logo
Logo